Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review.
Sim BL, Sim BZ, Tunbridge M, Liew DFL, Robinson PC.
J Rheumatol. 2023 Mar;50(3):400-407. doi: 10.3899/jrheum.220524. Epub 2022 Sep 1.
Myelosuppression and its consequences in elderly patients with cancer.
Balducci L.
Oncology (Williston Park). 2003 Nov;17(11 Suppl 11):27-32.
Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations.
Khaeso K, Udayachalerm S, Komvilaisak P, Chainansamit SO, Suwannaying K, Laoaroon N, Kuwatjanakul P, Nakkam N, Sukasem C, Puangpetch A, Tassaneeyakul W, Chaiyakunapruk N.
Front Pharmacol. 2021 Dec 2;12:784712. doi: 10.3389/fphar.2021.784712. eCollection 2021.
Cutting the brakes on hematopoietic regeneration by blocking TGFbeta to limit chemotherapy-induced myelosuppression.
Brenet F, Scandura JM.
Mol Cell Oncol. 2015 Apr 18;2(3):e978703. doi: 10.4161/23723556.2014.978703. eCollection 2015 Jul-Sep.
Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.
Goldschmidt J, Monnette A, Shi P, Venkatasetty D, Lopez-Gonzalez L, Huang H.
Future Oncol. 2022 Nov;18(35):3881-3894. doi: 10.2217/fon-2022-0754. Epub 2022 Nov 15.
IFN-zeta/ limitin: a member of type I IFN with mild lympho-myelosuppression.
Oritani K, Kanakura Y.
J Cell Mol Med. 2005 Apr-Jun;9(2):244-54. doi: 10.1111/j.1582-4934.2005.tb00353.x.
Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests.
Parchment RE, Gordon M, Grieshaber CK, Sessa C, Volpe D, Ghielmini M.
Ann Oncol. 1998 Apr;9(4):357-64. doi: 10.1023/a:1008245906772.
Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.
Hart L, Ogbonnaya A, Boykin K, Deyoung K, Bailey R, Heritage T, Lopez-Gonzalez L, Huang H, Gordan L.
Cancer Med. 2023 Apr;12(8):10020-10030. doi: 10.1002/cam4.5738. Epub 2023 Mar 31.
Predictors of Myelosuppression for Patients with Head and Neck Squamous Cell Carcinoma After Induction Chemotherapy.
Chen WQ, Peng L, Zeng XL, Wen WP, Sun W.
Clin Med Insights Oncol. 2024 Jan 5;18:11795549231219497. doi: 10.1177/11795549231219497. eCollection 2024.
Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene.
Boesen JJ, Nooter K, Valerio D.
Biotherapy. 1993;6(4):291-302. doi: 10.1007/BF01878359.
